— Biotechnology company Amicus Therapeutics (NASDAQ: FOLD) reported a net loss of $356.4 million or $1.48 per share for fiscal 2019, compared to a loss of $349 million or $1.88 per share in the preceding year.
— Total revenues nearly doubled to $182.2 billion in 2019 from $91.25 million in 2018
— Adjusted operating expenses were $464.3 million in 2019, up 14% compared to fiscal 2018
— Expects revenues of Galafold, a therapy for Fabry disease in adults, to be in the range of $250 million to $260 million in fiscal 2020
— Estimates full-year operating expense to be in the range of $410 million to $420 million, which represents an increase from last year
— On track to continue ongoing operations well into 2022, making use of the current cash position
— Looks to complete Pompe Phase-3 PROPEL study, enroll pediatric studies and advance manufacturing to support 2021 BLA and MAA
Most Popular
COVID-19 drove retailers up the digital path years ahead than anticipated
Earlier we looked into how, during the COVID-19 pandemic, retailers saw changing trends in terms of their assortments and how the acceleration of online shopping led many of them to
Snowflake (SNOW) creates a record as the most successful software IPO ever; stock more than doubles
Data is at the heart of business innovation. Recognizing this trend, companies are seeking ways to transform their businesses by capturing, analyzing, and mobilizing data. The public cloud is becoming
Adobe (ADBE) sees new tailwinds as virtual shift gathers steam
The second half has been highly rewarding for design software maker Adobe Inc. (NASDAQ: ADBE) amid stable demand for digital content solutions. The company has remained unaffected by the virus-related